These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20471224)

  • 41. Cannabis use and age at onset of schizophrenia.
    Veen ND; Selten JP; van der Tweel I; Feller WG; Hoek HW; Kahn RS
    Am J Psychiatry; 2004 Mar; 161(3):501-6. PubMed ID: 14992976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction.
    Dubertret C; Bidard I; Adès J; Gorwood P
    Schizophr Res; 2006 Sep; 86(1-3):284-90. PubMed ID: 16806837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder.
    Hooper SR; Woolley D; De Bellis MD
    Psychopharmacology (Berl); 2014 Apr; 231(8):1467-77. PubMed ID: 24619597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia.
    Leeson VC; Harrison I; Ron MA; Barnes TR; Joyce EM
    Schizophr Bull; 2012 Jun; 38(4):873-80. PubMed ID: 21389110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlates, change and 'state or trait' properties of insight in schizophrenia.
    Wiffen BD; Rabinowitz J; Lex A; David AS
    Schizophr Res; 2010 Sep; 122(1-3):94-103. PubMed ID: 20382507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
    Díaz I; Pelayo-Terán JM; Pérez-Iglesias R; Mata I; Tabarés-Seisdedos R; Suárez-Pinilla P; Vázquez-Barquero JL; Crespo-Facorro B
    Psychiatry Res; 2013 Apr; 206(2-3):181-7. PubMed ID: 23159063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Altered cortical maturation in adolescent cannabis users with and without schizophrenia.
    Epstein KA; Kumra S
    Schizophr Res; 2015 Mar; 162(1-3):143-52. PubMed ID: 25600549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Item response theory analysis of lifetime cannabis-use disorder symptom severity in an American Indian community sample.
    Gilder DA; Lau P; Ehlers CL
    J Stud Alcohol Drugs; 2009 Nov; 70(6):839-49. PubMed ID: 19895760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
    Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
    Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
    van Nimwegen LJ; de Haan L; van Beveren NJ; van der Helm M; van den Brink W; Linszen D
    Can J Psychiatry; 2008 Jun; 53(6):400-5. PubMed ID: 18616861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gender differences in health-related quality of life among cannabis users: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
    Lev-Ran S; Imtiaz S; Taylor BJ; Shield KD; Rehm J; Le Foll B
    Drug Alcohol Depend; 2012 Jun; 123(1-3):190-200. PubMed ID: 22143039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.
    Ritsner M; Gibel A; Perelroyzen G; Kurs R; Jabarin M; Ratner Y
    J Clin Psychopharmacol; 2004 Dec; 24(6):582-91. PubMed ID: 15538118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The relationship between sex and functional outcome in first-episode schizophrenia: the role of premorbid adjustment and insight.
    Ventura J; Subotnik KL; Han S; Hellemann GS; Green MF; Nuechterlein KH
    Psychol Med; 2023 Oct; 53(14):6878-6887. PubMed ID: 38314778
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Premorbid functioning of patients with first-episode nonaffective psychosis: a comparison of deterioration in academic and social performance, and clinical correlates of Premorbid Adjustment Scale scores.
    Monte RC; Goulding SM; Compton MT
    Schizophr Res; 2008 Sep; 104(1-3):206-13. PubMed ID: 18657952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Premorbid adjustment and remission of positive symptoms in first-episode psychosis.
    Amminger GP; Resch F; Mutschlechner R; Friedrich MH; Ernst E
    Eur Child Adolesc Psychiatry; 1997 Dec; 6(4):212-8. PubMed ID: 9443000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cannabis use and age of diagnosis of schizophrenia.
    Sugranyes G; Flamarique I; Parellada E; Baeza I; Goti J; Fernandez-Egea E; Bernardo M
    Eur Psychiatry; 2009 Jun; 24(5):282-6. PubMed ID: 19324529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
    Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
    Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.